Loading...
•
Mar 31, 2020
Alector Q1 2020 Earnings Report
Alector reported financial results for the first quarter ended March 31, 2020.
Key Takeaways
Alector reported collaboration revenue of $7.2 million and a net loss of $40.0 million for the quarter ended March 31, 2020. The company's cash, cash equivalents, and marketable securities were $548.5 million as of March 31, 2020.
Continued execution across immuno-neurology platform.
On track to initiate pivotal Phase 3 trial of AL001 in patients with frontotemporal dementia with a progranulin mutation (FTD-GRN) and a Phase 2 study of AL002 in Alzheimer’s disease patients in 2020.
Strong cash and investments position of $548.5 million to support execution of clinical, research, and operational goals.
Alector entered into a regional licensing agreement with Innovent Biologics for the development and commercialization of AL008 in oncology indications in China.
Revenue by Segment
Forward Guidance
Alector remains on track with previously stated guidance to initiate a pivotal Phase 3 study of AL001 in FTD-GRN patients in 2020 and also intends to initiate a Phase 2 study of AL002 in Alzheimer’s disease patients in 2020. The Company believes that its cash and investments as of March 31, 2020 will be sufficient to fund its anticipated operations through 2022.
Positive Outlook
- The Company remains on track to advance AL001 into a pivotal Phase 3 study in FTD-GRN patients in 2020.
- Alector expects to present preliminary Phase 2 data of AL001 in FTD-GRN patients at medical meetings in 2020.
- Initial Phase 1a data of AL101 in healthy volunteers are also expected during in 2020.
- Alector has closed enrollment for the Phase 1b study of AL002 and will proceed with initiating a Phase 2 trial in Alzheimer’s disease patients in 2020.
- Alector plans to initiate Phase 1 development for AL014 within the next 12 months.
Challenges Ahead
- As the COVID-19 pandemic continues to evolve, it could impact Alector’s programs in the future.
- Currently, certain clinical trial sites have delayed enrollment of new patients and paused clinical trial visits across clinical development programs.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...